Total Payments
$1,118
2024 Payments
$120.22
Companies
10
Transactions
19
Medicare Patients
9,040
Medicare Billing
$689,219
Payment Breakdown by Category
Food & Beverage$1,118 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,118 | 19 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $205.88 | 2 | $0 (2019) |
| Amgen Inc. | $158.64 | 2 | $0 (2018) |
| Novo Nordisk Inc | $136.22 | 2 | $0 (2024) |
| Allergan Inc. | $133.91 | 1 | $0 (2017) |
| AMAG Pharmaceuticals, Inc. | $125.00 | 1 | $0 (2018) |
| AbbVie Inc. | $119.54 | 7 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $114.70 | 1 | $0 (2019) |
| IDORSIA PHARMACEUTICALS US INC | $84.81 | 1 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $22.32 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $17.14 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120.22 | 1 | Novo Nordisk Inc ($120.22) |
| 2022 | $84.81 | 1 | IDORSIA PHARMACEUTICALS US INC ($84.81) |
| 2021 | $159.00 | 9 | AbbVie Inc. ($119.54) |
| 2020 | $16.00 | 1 | Novo Nordisk Inc ($16.00) |
| 2019 | $218.97 | 2 | Merck Sharp & Dohme Corporation ($114.70) |
| 2018 | $250.00 | 2 | AMAG Pharmaceuticals, Inc. ($125.00) |
| 2017 | $269.16 | 3 | Allergan Inc. ($133.91) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/16/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $120.22 | General |
| Category: Obesity | ||||||
| 11/21/2022 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $84.81 | General |
| Category: INSOMNIA | ||||||
| 10/26/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: NEUROSCIENCE | ||||||
| 08/03/2021 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.14 | General |
| Category: Cardiovascular | ||||||
| 07/09/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: NEUROSCIENCE | ||||||
| 06/17/2021 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: NEPHROLOGY | ||||||
| 04/27/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $4.32 | General |
| Category: NEUROSCIENCE | ||||||
| 04/06/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: NEUROSCIENCE | ||||||
| 03/15/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: NEUROSCIENCE | ||||||
| 03/09/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: NEUROSCIENCE | ||||||
| 01/27/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2020 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $16.00 | General |
| 03/05/2019 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $104.27 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/10/2019 | Merck Sharp & Dohme Corporation | GARDASIL (Biological) | Food and Beverage | In-kind items and services | $114.70 | General |
| Category: VACCINE | ||||||
| 10/17/2018 | Amgen Inc. | Prolia (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Endocrinology | ||||||
| 07/25/2018 | AMAG Pharmaceuticals, Inc. | INTRAROSA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: TREATMENT OF DYSPAREUNIA | ||||||
| 08/22/2017 | Amgen Inc. | Corlanor (Drug), Repatha | Food and Beverage | In-kind items and services | $33.64 | General |
| Category: Cardiology | ||||||
| 05/16/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $101.61 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/18/2017 | Allergan Inc. | BOTOX OAB (Drug) | Food and Beverage | In-kind items and services | $133.91 | General |
| Category: OVER ACTIVE BLADDER | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,469 | 3,374 | $372,590 | $198,857 |
| 2022 | 20 | 2,173 | 2,954 | $356,900 | $185,330 |
| 2021 | 18 | 2,208 | 2,811 | $320,045 | $168,977 |
| 2020 | 17 | 2,190 | 2,842 | $301,080 | $136,055 |
Total Patients
9,040
Total Services
11,981
Medicare Billing
$689,219
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 362 | 527 | $79,050 | $47,913 | 60.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 321 | 321 | $64,200 | $44,775 | 69.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 322 | 696 | $83,520 | $42,375 | 50.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 36 | 36 | $10,800 | $10,174 | 94.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 127 | 128 | $9,600 | $9,177 | 95.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 67 | $13,400 | $9,135 | 68.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 73 | $10,950 | $7,245 | 66.2% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 24 | 29 | $10,150 | $5,108 | 50.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 374 | 592 | $8,880 | $4,956 | 55.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 127 | 128 | $4,480 | $4,278 | 95.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 15 | 15 | $5,250 | $3,620 | 68.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 270 | 296 | $59,200 | $3,167 | 5.3% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 16 | 16 | $3,200 | $2,682 | 83.8% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 321 | 378 | $5,670 | $1,482 | 26.1% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 40 | 40 | $1,400 | $1,337 | 95.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $1,650 | $1,063 | 64.4% |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | Office | 2023 | 21 | 21 | $1,190 | $371.49 | 31.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 365 | 522 | $78,300 | $48,754 | 62.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 290 | 290 | $58,000 | $41,439 | 71.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 289 | 575 | $69,000 | $34,758 | 50.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 166 | $24,900 | $12,616 | 50.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 61 | 73 | $14,600 | $10,251 | 70.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 113 | 116 | $8,700 | $7,849 | 90.2% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 29 | 32 | $11,200 | $5,453 | 48.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 115 | 118 | $4,130 | $3,878 | 93.9% |
About Dr. Joan Feltman, M.D
Dr. Joan Feltman, M.D is a Internal Medicine healthcare provider based in Santa Monica, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053418640.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joan Feltman, M.D has received a total of $1,118 in payments from pharmaceutical and medical device companies, with $120.22 received in 2024. These payments were reported across 19 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($1,118).
As a Medicare-enrolled provider, Feltman has provided services to 9,040 Medicare beneficiaries, totaling 11,981 services with total Medicare billing of $689,219. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Santa Monica, CA
- Active Since 09/17/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1053418640
Products in Payments
- BOTOX OAB (Drug) $133.91
- INTRAROSA (Drug) $125.00
- Prolia (Biological) $125.00
- Wegovy (Drug) $120.22
- GARDASIL (Biological) $114.70
- IMFINZI (Drug) $104.27
- FARXIGA (Drug) $101.61
- QUVIVIQ (Drug) $84.81
- UBRELVY (Drug) $75.50
- VRAYLAR (Drug) $44.04
- Corlanor (Drug) $33.64
- JYNARQUE (Drug) $22.32
- ELIQUIS (Drug) $17.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Santa Monica
Dr. Przemyslaw Twardowski, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Richard Finn, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Saeed Sadeghi, Md, MD
Internal Medicine — Payments: $809,489
Internal Medicine $809,489
Zev Wainberg, Md, MD
Internal Medicine — Payments: $745,774
Internal Medicine $745,774
Dr. Stephen Kania, M.d, M.D
Internal Medicine — Payments: $707,242
Internal Medicine $707,242
Dr. Jonathan Goldman, M.d, M.D
Internal Medicine — Payments: $264,528
Internal Medicine $264,528